AsthmaPhase 2LevanteNCT06529419

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

A Phase 2 study testing AZD8630 and Inhaler in people with Asthma, run by AstraZeneca at 196 sites in 23 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA). Read more about this study

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Asthma
What is being tested?: AZD8630 and Inhaler
Type of treatment: Medical device
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 537 participants
Where: 196 sitesin 23 countries
Study dates: 30 Aug 2024to 4 Feb 2026
Phase: Phase 2
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Principal inclusion criteria (abbreviated):

Patient must be 18 to 80 years of age inclusive
Documented physician diagnosis of asthma for at least 12 months, with objective evidence of asthma (spirometric, bronchial challenge, exercise challenge or therapeutic response) within the last 5 years
Uncontrolled asthma (i.e. ACQ-6 ≥ 1.5)
Pre-BD FEV1 ≥ 40%
A history of asthma exacerbations within the last 12 months
\& 9. Compliant with asthma background mediation, daily ePROs and daily home spirometry.
BMI within the range 18-37 kg/m2 (inclusive)
Female patients of child bearing potential must not be pregnant and agree to use highly effective contraception.
Male patients and their female partners of childbearing potential must agree to use highly effective contraception.
Capable of giving signed informed consent.

Principal exclusion criteria (abbreviated):

History of life-threatening asthma
Recently completed treatment for respiratory infection and/or asthma exacerbation
Clinically important pulmonary disease other than asthma; including but not limited to those with co-existent chronic obstructive pulmonary disease.
Any disorder that is not stable in the opinion of the Investigator and could:
Affect the safety of the patient throughout the study
Influence the findings of the study or their interpretation
Impede the patient's ability to complete the entire duration of study
Patients who, in the opinion of the Investigator, have evidence of active TB or are currently on treatment for active or latent TB.
Medical history of or treatment for hepatitis B or hepatitis C, except for cured hepatitis C
Patients with history of HIV infection or who test positive for HIV.
Congenital long QT syndrome or prolonged QTcF > 470 ms or history of QT prolongation associated with other medications that required discontinuation of that medication.
Current untreated or uncontrolled arrhythmia.
Patients with recent myocardial infarction, unstable angina pectoris, stroke, percutaneous coronary intervention or coronary artery bypass grafting.
A helminth parasitic infection diagnosed that has not been treated, or has not responded to SoC therapy.
Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months ago.
Known history of drug or alcohol abuse within 12 months, that in the Investigator's opinion would preclude participation in the study.
Current diagnosis of cancer or unresectable cancer that has not been in complete remission for at least 5 years.
Any other clinically relevant abnormal findings that in the opinion of the Investigator or medical monitor might compromise the safety of the patient in the study or interfere with evaluation of the study intervention.
Treatment with marketed or investigational biologics within 4 months or a minimum of 5 half-lives.
Treatment with Systemic steroids within 4 weeks.
Chronic oral or systemic CS use for asthma or for any other indication (with the exception of stable replacement therapy in adrenal insufficiency).

Trial locations and contacts

196 sites in 23 countries.

Country

City, postcode or hospital

196 sites in 23 countries

United States45 sites

Research Site
American Fork, Utah, 84003
Research Site
Ames, Iowa, 50010
Research Site
Ann Arbor, Michigan, 48109
Research Site
Austin, Texas, 78704
Research Site
Baltimore, Maryland, 21237
Research Site
Beavercreek, Ohio, 45431
Research Site
Chicago, Illinois, 60616
Research Site
DeBary, Florida, 32713
Research Site
Detroit, Michigan, 48202
Research Site
Greenville, North Carolina, 27834
Research Site
Hampton, Virginia, 23666
Research Site
Horsham, Pennsylvania, 19044
Research Site
Huntington Beach, California, 92647
Research Site
Jacksonville, Florida, 32216
Research Site
Jensen Beach, Florida, 34957
Research Site
Kansas City, Kansas, 66160
Research Site
La Mesa, California, 91942
Research Site
Laguna Niguel, California, 92677
Research Site
Lancaster, California, 93534
Research Site
Largo, Florida, 33777
Research Site
Las Vegas, Nevada, 89102
Research Site
Las Vegas, Nevada, 89119
Research Site
Lilburn, Georgia, 30047
Research Site
Lima, Ohio, 45801
Research Site
Long Beach, California, 90815
Research Site
McKinney, Texas, 75069
Research Site
Mesa, Arizona, 85213
Research Site
Mesquite, Texas, 75149
Research Site
Methuen, Massachusetts, 01844
Research Site
Miami, Florida, 33135
Research Site
Miami Lakes, Florida, 33014
Research Site
Middletown, New York, 10941
Research Site
Milwaukee, Wisconsin, 53228
Research Site
New Haven, Connecticut, 06510
Research Site
Oklahoma City, Oklahoma, 73120
Research Site
Pearland, Texas, 77584
Research Site
Riverdale, New Jersey, 07457
Research Site
Roy, Utah, 84067
Research Site
Salt Lake City, Utah, 84124
Research Site
San Antonio, Texas, 78215
Research Site
San Jose, California, 95117
Research Site
Savannah, Georgia, 31406
Research Site
Tampa, Florida, 33607
Research Site
Winfield, Illinois, 60190
Research Site
Winston-Salem, North Carolina, 27104

Other trials in United States

China19 sites

Research Site
Baotou, 014010
Research Site
Changchun, 130021
Research Site
Chengdu, 610078
Research Site
Chongqing, 401320
Research Site
Guangzhou, 510163
Research Site
Guiyang, 510630
Research Site
Hefei, 230061
Research Site
Hohhot, 010010
Research Site
Jinan, 250021
Research Site
Lanzhou, 730000
Research Site
Nanchang, 330006
Research Site
Ningbo, 315010
Research Site
Qingdao, 266011
Research Site
Shanghai, 200080
Research Site
Shenyang, 110004
Research Site
Shijiazhuang, 050051
Research Site
Taiyuan, 030032
Research Site
Wenzhou, 325027
Research Site
Xuzhou, 221000

Other trials in China

Japan18 sites

Research Site
Chūōku, 104-0031
Research Site
Fukuoka, 819-8555
Research Site
Hiratsuka-shi, 254-8502
Research Site
Hiroshima, 730-0013
Research Site
Kitakyushu, 802-0052
Research Site
Kusatsu-shi, 525-8585
Research Site
Maebashi, 371-0048
Research Site
Maebashi, 371-0054
Research Site
Meguro-ku, 153-8515
Research Site
Mizunami-shi, 509-6134
Research Site
Nankoku-shi, 783-8509
Research Site
Niigata, 950-1197
Research Site
Sakaishi, 591-8555
Research Site
Sapporo, 064-0804
Research Site
Shinjuku-ku, 162-8655
Research Site
Toyoake-shi, 470-1192
Research Site
Yanagawa-shi, 832-0059
Research Site
Yokohama, 236-0037

Other trials in Japan

Ukraine11 sites

Research Site
Chernivtsі, 58002
Research Site
Ivano-Frankivsk, 76018
Research Site
Ivano-Frankivsk, 76019
Research Site
Kyiv, 02002
Research Site
Kyiv, 02081
Research Site
Kyiv, 03037
Research Site
Kyiv, 03049
Research Site
Kyiv, 03680
Research Site
Lutsk, 43000
Research Site
Uzhhorod, 88018
Research Site
Vinnytsia, 21029

Other trials in Ukraine

Argentina9 sites

Research Site
Alberdi, X5033DCE
Research Site
CABA, C1426
Research Site
Capital Federal, C1060ABN
Research Site
Mar del Plata, 7600
Research Site
Quilmes, B1878FNR
Research Site
Rosario, 2000
Research Site
San Fernando, B1646EBJ
Research Site
San Juan Bautista, 1888
Research Site
San Miguel de Tucumán, 4000

Other trials in Argentina

Czechia8 sites

Research Site
Brno, 62500
Research Site
Hradec Králové, 50005
Research Site
Jindřichův Hradec, 377 01
Research Site
Kralupy nad Vltavou, 278 01
Research Site
Pilsen, 32300
Research Site
Prague, 15300
Research Site
Teplice, 415 01
Research Site
Varnsdorf, 407 47

Other trials in Czechia

Germany8 sites

Research Site
Berlin, 10119
Research Site
Bonn, 53127
Research Site
Essen, 45239
Research Site
Frankfurt, 60596
Research Site
Landsberg, 86899
Research Site
Leipzig, 04207
Research Site
Mainz, 55128
Research Site
Marburg, 35037

Other trials in Germany

Spain8 sites

Research Site
Barcelona, 8035
Research Site
Benalmádena, 29631
Research Site
Madrid, 28041
Research Site
Majadahonda, 28222
Research Site
Málaga, 29010
Research Site
Palma de Mallorca, 07010
Research Site
Santander, 39008
Research Site
Valencia, 46010

Other trials in Spain

Slovakia7 sites

Research Site
Kežmarok, 060 01
Research Site
Košice, 04022
Research Site
Levice, 93401
Research Site
Prešov, 081 81
Research Site
Topoľčany, 955 01
Research Site
Topoľčany, 95501
Research Site
Žilina, 010 01

Other trials in Slovakia

Taiwan7 sites

Research Site
Kaohsiung City, 80756
Research Site
Taichung, 40705
Research Site
Taichung, 433004
Research Site
Taipei, 0116
Research Site
Taipei, 100
Research Site
Taipei, 110
Research Site
Taoyuan, 333

Other trials in Taiwan

Chile6 sites

Research Site
Chile, 7770484
Research Site
Curicó, 3341643
Research Site
Santiago, 7500587
Research Site
Santiago, 7500691
Research Site
Talca, 3465584
Research Site
Viña del Mar, 2540488

Other trials in Chile

Denmark6 sites

Research Site
Aalborg, 9100
Research Site
Hvidovre, 2650
Research Site
København NV, 2400
Research Site
Odense, 5000
Research Site
Roskilde, 4000
Research Site
Vejle, 7100

Other trials in Denmark

South Africa6 sites

Research Site
Cape Town, 7700
Research Site
Durban, 4001
Research Site
eMkhomazi, 4170
Research Site
Observatory, 7925
Research Site
Somerset West, 7130
Research Site
Tygervalley, 7530

Other trials in South Africa

Turkey (Türkiye)6 sites

Research Site
Adana, 1330
Research Site
Altındağ-Ankara, 06230
Research Site
Ankara
Research Site
Istanbul, 34854
Research Site
Kirikkale, 71450
Research Site
Mersin, 33079

Other trials in Turkey (Türkiye)

France5 sites

Research Site
Lyon, 69317
Research Site
Marseille, 13915
Research Site
Nice, F-06002
Research Site
Paris, 75018
Research Site
Reims, 51092

Other trials in France

Mexico5 sites

Research Site
Durango, 34200
Research Site
Guadalajara, 44130
Research Site
Monterrey, 64040
Research Site
Monterrey, 64710
Research Site
Villahermosa, 86035

Other trials in Mexico

South Korea5 sites

Research Site
Daegu, 42415
Research Site
Seoul, 03312
Research Site
Seoul, 06591
Research Site
Seoul, 3722
Research Site
Seoul, 5505

Other trials in South Korea

Israel4 sites

Research Site
Ashkelon, 78278
Research Site
Jerusalem, 9372212
Research Site
Rehovot, 76100
Research Site
Tel Aviv, 6423906

Other trials in Israel

Italy4 sites

Research Site
Genoa, 16132
Research Site
Milan, 20122
Research Site
Roma, 00168
Research Site
Roma, 161

Other trials in Italy

Belgium3 sites

Research Site
Duffel, 2570
Research Site
Mechelen, 2800
Research Site
Namur, 5101

Other trials in Belgium

United Kingdom3 sites

Research Site
Bradford, BD9 6RJ
Research Site
Liverpool, L7 8XP
Research Site
Portsmouth, PO6 3LY

Other trials in United Kingdom

Netherlands2 sites

Research Site
Alkmaar, 1815 JD
Research Site
Amersfoort, 3813 TZ

Other trials in Netherlands

Hong Kong1 site

Research Site
Hong Kong

Other trials in Hong Kong

About this study

Official title: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults With Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)

Read the detailed description

This is a Phase II, randomised, placebo-controlled, double-blind, dose range-finding, multi-centre study to assess the efficacy and safety of inhaled AZD8630 administered at 3 doses via an inhaler in adult patients with uncontrolled asthma, at risk of an exacerbation. The study duration up to 57 weeks for participants in the optional safety extension study and up to 17 weeks for those not included. The maximal treatment period is up to 52 weeks.

This study will be conducted in approximately 220 centres in 20-25 countries. Approximately 516 patients will be randomised globally

Conditions: Asthma
Being tested: AZD8630, Placebo, Inhaler
Medical subject headings: Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

AZD8630Drug
The drug will be administered by inhalation
PlaceboDrug
The placebo will be administered by inhalation
InhalerDevice
The drug/placebo will be administered by inhalation using the inhaler

Study groups in NCT06529419
Study group	Role	What they receive
AZD8630 dose A	Experimental	Inhaled AZD8630 administered at a dose A Receives: Drug: AZD8630; Device: Inhaler
AZD8630 dose B	Experimental	Inhaled AZD8630 administered at a dose B Receives: Drug: AZD8630; Device: Inhaler
AZD8630 dose C	Experimental	Inhaled AZD8630 administered at a dose C Receives: Drug: AZD8630; Device: Inhaler
Placebo	Placebo comparator	Inhaled placebo Receives: Drug: Placebo; Device: Inhaler

What is being measured

The primary outcome is the main question the study is designed to answer.

Time to first CompEx Asthma event
The CompEx Asthma is a composite endpoint for exacerbations that captures asthma-worsening episodes based on combination of diary events (worsening in daily PEF, asthma symptoms and rescue medication use) plus severe asthma exacerbation events. Diary events are defined by threshold and slope criteria using the following morning/evening diary variables:
- PEF
- Asthma symptom score (0 to 3)
- Use of rescue medication
Measured: 12 weeks

Secondary outcomes (5)

Pre-BD FEV1
Change from baseline in pre-bronchodilator forced expiratory volume in 1 second.
Measured: 12 weeks
ACQ-6:
Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6). The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease
Measured: 12 weeks
AQLQ12+
Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older. The AQLQ12+ includes 32 questions grouped into four domains: symptoms; activity limitations; emotional function; and, environmental stimuli. Each question is scored on a seven-point Likert scale, which ranges from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean of all questions, and the four domain scores are the means of the scores for the questions in the respective domains
Measured: 12 weeks
SGRQ
Change from baseline in the St. George's Respiratory Questionnaire. The SGRQ includes 50 questions grouped into two parts: Part 1 : Symptoms component (frequency \& severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall.
Measured: 12 weeks
FeNO
Change from baseline to: FeNO: Weeks 1, 2, 4, 8, and 12
Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Aug 20244 Feb 2026

First posted31 Jul 2024
Study start30 Aug 2024
Primary completion4 Feb 2026
Study completion4 Feb 2026

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for AsthmaStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: This is a parallel-group treatment study with 4 arms that is patient and Investigator blinded. Patients will be randomly assigned in a 1:1:1:1 ratio to one of the 4 treatment arms.
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 537 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06529419
Sponsor's protocol ID: D6830C00003
Acronym: Levante
Status last verified: Feb 2026
First submitted: 15 Jul 2024
Last updated: 2 Mar 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: Yes

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
Asthma
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
RecruitingPhase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Asthma
Active, not recruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Asthma

All Asthma trials

Study at a glance

From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults With Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)
ClinicalTrials.gov ID: NCT06529419
Acronym / sponsor ID: Levante / D6830C00003
Conditions: Asthma
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 537 participants (actual)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 30 Aug 2024 (actual)
Primary completion: 4 Feb 2026 (actual)
Study completion: 4 Feb 2026 (actual)
First posted: 31 Jul 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

This study will be conducted in approximately 220 centres in 20-25 countries. Approximately 516 patients will be randomised globally

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 4
Model description: This is a parallel-group treatment study with 4 arms that is patient and Investigator blinded. Patients will be randomly assigned in a 1:1:1:1 ratio to one of the 4 treatment arms.

Arm	Type	Receives
AZD8630 dose A	Experimental	Drug: AZD8630, Device: InhalerInhaled AZD8630 administered at a dose A
AZD8630 dose B	Experimental	Drug: AZD8630, Device: InhalerInhaled AZD8630 administered at a dose B
AZD8630 dose C	Experimental	Drug: AZD8630, Device: InhalerInhaled AZD8630 administered at a dose C
Placebo	Placebo comparator	Drug: Placebo, Device: InhalerInhaled placebo

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
AZD8630The drug will be administered by inhalation	Drug	AZD8630 dose A, AZD8630 dose B, AZD8630 dose C
PlaceboThe placebo will be administered by inhalation	Drug	Placebo
InhalerThe drug/placebo will be administered by inhalation using the inhaler	Device	AZD8630 dose A, AZD8630 dose B, AZD8630 dose C, Placebo

Primary outcome

Time to first CompEx Asthma event
Time frame: 12 weeks
The CompEx Asthma is a composite endpoint for exacerbations that captures asthma-worsening episodes based on combination of diary events (worsening in daily PEF, asthma symptoms and rescue medication use) plus severe asthma exacerbation events. Diary events are defined by threshold and slope criteria using the following morning/evening diary variables: * PEF * Asthma symptom score (0 to 3) * Use of rescue medication

5 secondary outcomes

Pre-BD FEV1
Time frame: 12 weeks
ACQ-6:
Time frame: 12 weeks
AQLQ12+
Time frame: 12 weeks
SGRQ
Time frame: 12 weeks
FeNO
Time frame: 12 weeks

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.

Related trials for Asthma

RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
Asthma
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
RecruitingPhase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Asthma
Active, not recruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Asthma

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Njira Lugogo principal investigator

Univeristy of Michigan Hospital, Ann Arbor, MI, US

196 sites in 23 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AZD8630 and Inhaler in people with Asthma, run by AstraZeneca at 196 sites in 23 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 196 sites in United States, China, Japan, Ukraine, Argentina and 18 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to first CompEx Asthma event (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06529419.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.